Turnitin
降AI改写
早检测系统
早降重系统
Turnitin-UK版
万方检测-期刊版
维普编辑部版
Grammarly检测
Paperpass检测
checkpass检测
PaperYY检测
[HTML][HTML] Colorectal cancer: genetic abnormalities, tumor progression, tumor heterogeneity, clonal evolution and tumor-initiating cells
Colon cancer is the third most common cancer worldwide. Most colorectal cancer
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …
occurrences are sporadic, not related to genetic predisposition or family history; however, 20 …
From tumour heterogeneity to advances in precision treatment of colorectal cancer
In recent years, the high heterogeneity of colorectal cancer (CRC) has become evident.
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …
Hence, biomarkers need to be developed that enable the stratification of patients with CRC …
Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches
Gastric cancer is one of the most aggressive malignancies, with limited treatment options in
both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic …
both locally advanced and metastatic setting, resulting in poor prognosis. Based on genomic …
[HTML][HTML] Implementing anti-epidermal growth factor receptor (EGFR) therapy in metastatic colorectal cancer: challenges and future perspectives
Highlights•The epidermal growth factor (EGFR) is a therapeutic option for patients with all
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …
RAS WT metastatic colorectal cancer (mCRC).•A better knowledge of the mechanism of …
The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios
The term liquid biopsy refers to the analysis of biomarkers in any body fluid, including blood,
urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor …
urine and cerebrospinal fluid. In cancer, liquid biopsy testing allows the analysis of tumor …
Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer
Abstract Purpose: Even if RAS-BRAF wild-type and HER2/MET–negative metastatic
colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired …
colorectal cancer (mCRC) patients frequently respond to anti-EGFR mAbs, acquired …
[HTML][HTML] BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis
Background While the negative prognostic role of BRAF V600E mutation in metastatic
colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596 …
colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596 …
PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials
N Dey, P De, B Leyland-Jones - Pharmacology & therapeutics, 2017 - Elsevier
Breast cancer (BC) is the most common women cancer and second most common cause of
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …
cancer death in women. A woman living in the United States has 12.3% lifetime risk of being …
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
The prognosis of patients with metastatic colorectal cancer (mCRC) remain poor despite the
impressive improvement of treatments observed over the last 20 years that led to an …
impressive improvement of treatments observed over the last 20 years that led to an …
Clinicopathologic features and prognostic value of KRAS, NRAS and BRAF mutations and DNA mismatch repair status: A single‐center retrospective study of 1,834 …
Mutations of KRAS, NRAS, BRAF and DNA mismatch repair (MMR) status have become an
important part of the assessment of patients with colorectal cancer (CRC), while respective …
important part of the assessment of patients with colorectal cancer (CRC), while respective …